The News

Endotis Pharma presents data on the neutralizable anticoagulant EP217609 in an extracorporeal circulation model.

03/06/2010

Biocitech Park, Paris (France), June 3rd, 2010. Endotis Pharma announced that initial results* on the neutralizable anticoagulant EP217609 in a canine model of extracorporeal circulation (ECC) will be presented today, at the French Society of Thoracic and Cardiovascular Surgery's 63th annual meeting in Tours, France.

Both EP217609 and its specific antidote avidin were well tolerated in this clinically relevant animal study. A single dose of EP217609 resulted in efficient, stable anticoagulation throughout the ECC procedure. Subsequent administration of avidin produced rapid, complete, irreversible neutralization and no rebound effect. There was no evidence of clotting in the extracorporeal circuits.

Eric Neuhart, MD, Head of Clinical Research and Development at Endotis Pharma, commented:
“EP217609 and avidin could represent the first alternative to unfractionated heparin and its antidote protamine which, despite their known side effects and limitations, have been used during heart surgery for more than 50 years.”
EP217609 is a first-in-class synthetic, parenteral anticoagulant which can be neutralized by a specific antidote avidin (EP5001). EP217609 has a dual mechanism of action which combines direct (free and clot-bound) thrombin inhibition and indirect factor Xa inhibition.
In April, Endotis announced that EP217609 and its specific antidote avidin had successfully completed their respective first-in-man Phase I clinical trials and that a study assessing the neutralization of EP217609 by avidin in healthy subjects will be initiated this summer.* EP217609, a new neutralizable anticoagulant for cardiopulmonary bypass during cardiac surgery.

Y. Fromes1, E. Neuhart2, C. Krezel2, P. Gueret3, M. Petitou2. 1Institute of Myology, Pitié-Salpêtrière University Hospital - Department of Anesthesiology, St Joseph Hospital, Paris, France. 2Endotis Pharma, Romainville, France. 3Department of Hemostasis, Pontchaillou University Hospital, Rennes, France.

About Endotis Pharma
Endotis Pharma is a biopharmaceutical company dedicated to the discovery and development of small-glyco drugs for applications in thrombosis, oncology, hematology and a range of other indications. Endotis has developed a breakthrough thrombosis franchise of parenteral and oral drugs in clinical and preclinical development, and a promising oncology and hematology discovery platform. Endotis has 33 employees based in Paris and Lille, France.
Disclaimer: The development of new drug technologies is difficult, erratic and unpredictable. Endotis Pharma’s forecasts and future economic performance depend on research that has yet to be performed and on a number of other factors. The company's future economic performance may differ significantly from that currently forecast.

For more information
Press contact: Alize RP
Caroline Carmagnol
+33 (0)6 64 18 99 59
caroline@alizerp.com
Charles Catherinot
+ 33 (0)1 42 68 86 42
charles@alizerp.com
Endotis Pharma contact:
Denis Henrard
Head of Business Development and Licensing
denishenrard@endotis.com
+33 (0) 1 48 46 50 52